Interestingly, a recent analysis of more than 7, 000 cancer patients from the The Cancer Genome Atlas (TCGA) revealed that PD-L1 was only weakly associated with the magnitude of benefit from PD1/PD-L1 blockade, while the abundance of CD8+ T cells, tumor mutational burden (TMB) and the fraction of samples with high PD1 mRNA expression were more strongly predictive for the response to anti-PD1/PD-L1 agents [23]. Here, CD274 is linked to neoplasm.